Document is current
Any future updates will be listed below
-
Authors
Mentink, Lara J. https://orcid.org/0000-0003-4373-7910
van Osch, Matthias J. P.
Bakker, Leanne J.
Olde Rikkert, Marcel G. M.
Beckmann, Christian F.
Claassen, Jurgen A. H. R.
Haak, Koen V.
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (17854, 012-200-013, 016.160.351, 09150171910043, 016.Veni.171.068)
Alzheimer Nederland (WE.05-2010-04)
Wellcome Trust (215573/Z/19/Z)
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 26 October 2024
First Online: 12 November 2024
Declarations
:
: The SCHIP study was approved by the institutional review board (CMO, Commissie Mensgebonden Onderzoek, Region Arnhem-Nijmegen, NL55712.091.16, file number 2016–2337) and performed in accordance with good clinical practice guidelines and the world medical associations code of ethics (Declaration of Helsinki).
: Written informed consent was obtained from all participants after they received detailed study information. Participants received a stipend of 50 euros for participating.
: CFB is founder and shareholder of SBGneuro Ltd.
